Jun Yu Kyung, Koh Seong-Joon, Myung Dae Seong, Park Sang Hyoung, Ooi Choon Jin, Sood Ajit, Im Jong Pil
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Division of Gastroenterology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Intest Res. 2023 Jul;21(3):353-362. doi: 10.5217/ir.2023.00013. Epub 2023 Jul 27.
BACKGROUND/AIMS: Infectious complications are major concerns when treating patients with inflammatory bowel disease (IBD). This study evaluated clinical differences across countries/regions in the management of infectious diseases in patients with IBD.
A multinational online questionnaire survey was administered to participants at the 8th meeting of the Asian Organization for Crohn's and Colitis. The questionnaire included questions regarding surveillance, diagnosis, management, and prevention of infection in patients with IBD.
A total of 384 physicians responded to the questionnaire. The majority of Korean (n=70, 63.6%) and Chinese (n=51, 51.5%) physicians preferred vancomycin to metronidazole in the treatment of Clostridium difficile infection, whereas more than half of the Japanese physicians (n=62, 66.7%) preferred metronidazole. Physicians in Korea (n=88, 80.0%) and China (n=46, 46.5%) preferred a 3-month course of isoniazid and rifampin to treat latent tuberculosis infection, whereas most physicians in Japan (n=71, 76.3%) favored a 9-month course of isoniazid. Most Korean physicians (n=89, 80.9%) recommended hepatitis B virus (HBV) vaccination in patients lacking HBV surface antigen, whereas more than half of Japanese physicians (n=53, 57.0%) did not consider vaccination.
Differences in the diagnosis, prevention, and management of infections in patients with IBD across countries/regions reflect different prevalence rates of infectious diseases. This survey may broaden understanding of the real-world clinical settings across Asian countries/regions and provide information for establishing practical guidelines to manage patients with IBD.
背景/目的:在治疗炎症性肠病(IBD)患者时,感染性并发症是主要关注点。本研究评估了不同国家/地区在IBD患者感染性疾病管理方面的临床差异。
在亚洲克罗恩病和结肠炎组织第8次会议上,对参与者进行了一项跨国在线问卷调查。问卷包括有关IBD患者感染监测、诊断、管理和预防的问题。
共有384名医生回复了问卷。在治疗艰难梭菌感染时,大多数韩国医生(n = 70,63.6%)和中国医生(n = 51,51.5%)更倾向于使用万古霉素而非甲硝唑,而超过一半的日本医生(n = 62,66.7%)更倾向于使用甲硝唑。韩国医生(n = 88,80.0%)和中国医生(n = 46,46.5%)更倾向于使用异烟肼和利福平3个月疗程来治疗潜伏性结核感染,而大多数日本医生(n = 71,76.3%)则倾向于使用异烟肼9个月疗程。大多数韩国医生(n = 89,80.9%)建议对缺乏乙肝表面抗原的患者进行乙肝病毒(HBV)疫苗接种,而超过一半的日本医生(n = 53,57.0%)不考虑接种疫苗。
不同国家/地区IBD患者感染的诊断、预防和管理差异反映了传染病的不同流行率。这项调查可能会拓宽对亚洲国家/地区实际临床情况的理解,并为制定IBD患者管理的实用指南提供信息。